Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy

by Jinyu Zhang, Pablo Saenz-lopez Larrocha, Bin Zhang, Derek Wainwright, Payal Dhar, Jennifer D. Wu
Published 2019-08-01